Full Contract Development and Manufacturing Organization will continue to specialize in innovative cannabinoid solutions for the B2B market
MedCan Pharma A/S announced today the launch of a new corporate name and brand identity. The organization will now be known as NordicCan A/S. The new name is reflected in a new logo, domain name, www.nordiccan.com and related communication channels. NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, will continue to focus on helping brands around the world launch value-added products in the food supplement, medical and pharmaceutical categories.
“The change in our brand reflects our Nordic roots and commitment to developing and manufacturing safe, high quality and consumer-friendly oral and intra-oral dosage formats containing cannabinoids,” said Julie Malbaek, NordicCan CEO. “Over the past years, we have built a strong relationship with customers and partners around the world in the wellness, nutraceutical, medical and pharmaceutical categories. This is an exciting change for us. It brings us closer to our goal of becoming the preferred partner for best in world cannabinoids products for buccal release.”
With research and development (R&D) and manufacturing facilities in Denmark and Canada, NordicCan is strategically placed to serve existing and future markets with oral and intra-oral cannabinoid products. The site in Denmark is EU GMP approved and ready to develop, produce and pack cannabinoid products compliant with the European legislation and quality requirements. The site in Vancouver, Canada has been submitted for final processing license approval from Health Canada. The site is expected to be fully operational in 2021. The site will be GPP compliant according to the Canadian Cannabis Act, from development processes to the dispatch of finished cannabinoid products.
About NordicCan A/S
NordicCan Pharma, a sister company of Fertin Pharma, develops and produces innovative cannabinoid containing products based on innovative delivery systems. With a health focus, NordicCan defines its business scope within wellness, medicinal and pharmaceutical approved cannabinoid containing formats. Fertin Pharma and NordicCan jointly own a wide range of patents covering several oral and intra-oral delivery technologies, which offer the patient and consumer efficient, pleasurable and convenient delivery formats.
Read more about NordicCan Innovative delivery systems for cannabinoids https://nordiccan.com/delivery_systems/
For more information about this announcement, please contact:
NordicCan A/S
Julie Malbaek
CEO NordicCan A/S
JULM@fertin.com
www.nordiccan.com
